1006 related articles for article (PubMed ID: 15850584)
1. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
Ozakbas S; Cagiran I; Ormeci B; Idiman E
J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
[TBL] [Abstract][Full Text] [Related]
3. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
5. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
6. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
7. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
[TBL] [Abstract][Full Text] [Related]
8. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
9. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
10. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
11. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
[TBL] [Abstract][Full Text] [Related]
12. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
13. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
14. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
15. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
16. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
17. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
[TBL] [Abstract][Full Text] [Related]
18. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
[TBL] [Abstract][Full Text] [Related]
19. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
[TBL] [Abstract][Full Text] [Related]
20. [Sleepiness and fatigue in multiple sclerosis - comparison of different measuring instruments].
Kotterba S; Eren E; Fangerau T; Malin JP; Sindern E
Fortschr Neurol Psychiatr; 2003 Nov; 71(11):590-4. PubMed ID: 14608510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
